All sponsors

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS16
PHASE 3 / 2-310
RECRUITING11
READOUTS ≤12 MONTHS6
READOUT SLIPPED >6 MO0%

Delay Index: of 6 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
NCT06886126
NCT06886126
P2RecruitingObesity2402025-09-23
HDM1005 1
NCT07109700
P2RecruitingType 2 Diabetes2162026-01-31
HDM1702
NCT07036172
P3RecruitingObesity Control4602026-04
HDM1002 200mg, oral, once daily, 52 weeks
NCT06885021
P3Not yet recruitingOverweight and Obesity7802026-05-30
HDM1005 1
NCT07279194
P3RecruitingObesity & Overweight8252026-09-20
HDM1002 200 mg
NCT07193459
P3RecruitingType 2 Diabetes3602026-10-10
HDM1005 dose level 1
NCT07521631
P2RecruitingObesity3722027-02-04
HDM1002 100 mg
NCT07082114
P3RecruitingType 2 Diabetes8002027-02-16
Roflumilast Foam 0.3%
NCT07683806
P3RecruitingSeborrheic Dermatitis3092027-06-30
HDM1005 1
NCT07394114
P3RecruitingType 2 Diabetes2402027-08-28
HDM1005 1
NCT07417306
P3Not yet recruitingType 2 Diabetes9122027-08-30
HDM2005
NCT07124936
P1/2RecruitingDiffuse Large B Cell Lymphoma (DLBCL)972027-10-26
HDM2017
NCT07621159
P1/2Not yet recruitingColorectal Cancer Metastatic1202027-11-01
HDM1005
NCT07787260
P3Not yet recruitingObstructive Sleep Apnea (OSA) and Obesity2002028-03
HDM1005
NCT07794397
P3Not yet recruitingObstructive Sleep Apnea (OSA) and Obesity2002028-09
HDM2017
NCT07805551
P1/2RecruitingCRC, Colorectal Cancer2202030-08